239 related articles for article (PubMed ID: 23348585)
1. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Charette N; De Saeger C; Horsmans Y; Leclercq I; Stärkel P
Cell Death Dis; 2013 Jan; 4(1):e471. PubMed ID: 23348585
[TBL] [Abstract][Full Text] [Related]
2. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
3. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
[TBL] [Abstract][Full Text] [Related]
4. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications.
Jang JY; Kim SJ; Cho EK; Jeong SW; Park EJ; Lee WC; Lee SH; Kim SG; Kim YS; Kim HS; Kim BS; Lin W; Chung RT
PLoS One; 2014; 9(6):e98171. PubMed ID: 24927176
[TBL] [Abstract][Full Text] [Related]
5. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5.
Kang YJ; Kim IY; Kim EH; Yoon MJ; Kim SU; Kwon TK; Choi KS
Exp Mol Med; 2011 Jan; 43(1):24-34. PubMed ID: 21150246
[TBL] [Abstract][Full Text] [Related]
6. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
7. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
8. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.
Jayasooriya RG; Choi YH; Hyun JW; Kim GY
Environ Toxicol Pharmacol; 2014 Nov; 38(3):959-67. PubMed ID: 25461556
[TBL] [Abstract][Full Text] [Related]
9. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
[TBL] [Abstract][Full Text] [Related]
11. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
12. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
13. α-Hispanolol sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis via death receptor up-regulation.
Mota A; Jiménez-Garcia L; Herránz S; de Las Heras B; Hortelano S
Toxicol Appl Pharmacol; 2015 Aug; 286(3):168-77. PubMed ID: 25930665
[TBL] [Abstract][Full Text] [Related]
14. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
15. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
[TBL] [Abstract][Full Text] [Related]
17. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells.
Lee JY; Jung KH; Morgan MJ; Kang YR; Lee HS; Koo GB; Hong SS; Kwon SW; Kim YS
Mol Cancer Ther; 2013 Mar; 12(3):274-85. PubMed ID: 23053497
[TBL] [Abstract][Full Text] [Related]
19. Nutlin-3 Promotes TRAIL-Induced Liver Cancer Cells Apoptosis by Activating p53 to Inhibit bcl-2 and Surviving Expression.
Zhang C; Ni J; Fan W; Hou J
Ann Clin Lab Sci; 2022 Jul; 52(4):601-610. PubMed ID: 36197780
[TBL] [Abstract][Full Text] [Related]
20. Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis.
Szliszka E; Zydowicz G; Mizgala E; Krol W
Int J Oncol; 2012 Sep; 41(3):818-28. PubMed ID: 22735465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
